{"name":"Prexton Therapeutics","slug":"prexton-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PXT002331","genericName":"PXT002331","slug":"pxt002331","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"PXT002331","genericName":"PXT002331","slug":"pxt002331","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPVkFkdEl4YW5PU0czeDM0VEE5ZTZueWwzUGZsQUtfdUhtOV9uTWFEOTBZdnR0V01sVE5VV1ZhYXNfM0hCRVlyVXhxU2o5QkNaTDdiOGNxRWI2ZGZsTlEwbUJIVExDUmtVM1YwTno4Zld4LU9YaV9IbGVPV1M5NlBucDlKWWVnVmVKZFdtVnl3UWJHcHg5TW8zam1id0dOVEsyZnc0ZjBlbTVQR1RtUTdhVGIxNzhuUEotSVF6aU5B?oc=5","date":"2025-05-28","type":"pipeline","source":"Fierce Pharma","summary":"Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma","headline":"Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZnZpSTJyRXIwaFhMc3dsNjFjUlZpUENoOGx3WTF6TE5RUGd3MkZaS25vcWVZYVpQRTQ3Sm91ZmRwQ2JSM2hMRm5KMHRpV0JGQ1AzdzRFNXprVHgyQ0I5YXBiUjhBNEIxYkxTNk1TajlySzRXMC1KR2NHMF9ORkN3eVBRYzBGZXZPcVIyeFZHWWtnRFpl?oc=5","date":"2025-04-15","type":"pipeline","source":"Pharmaceutical Commerce","summary":"Reducing Risk in the Pharmaceutical Cold Chain - Pharmaceutical Commerce","headline":"Reducing Risk in the Pharmaceutical Cold Chain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBqRGFFalpsekYwa2dUNHgwYjByUE9ueFR4TGlUcWlXbnY1MWFFbDdjWmRmd3pzd3ZuWXlCTjV0YzFGMFJOaERuS0pnODZIelBNWlE1Z0lGemhxVmZ2dzVLX0NPcWRkcVc0SEVnU1FTU0E5MGZEMlB2eFhfbHozcFE?oc=5","date":"2024-04-16","type":"pipeline","source":"Business San Diego","summary":"Exclusive: Successful Biotech CEO Talks Scaling from Series A to $157M Series B - Business San Diego","headline":"Exclusive: Successful Biotech CEO Talks Scaling from Series A to $157M Series B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBLSzFmSzJRb05kcnBIYTZELXU3TUpwNGhNQkVFbXMwZzFXZmhuZzRyOFRGaFJlVXhVTEdjMnlrQXlGX3RzdEZmT0pfeVZvcHBFOTlZZ3VtRFVXWFpj?oc=5","date":"2024-03-15","type":"trial","source":"EurekAlert!","summary":"UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment - EurekAlert!","headline":"UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNbjlZSHNYQ3F2MWllY0V6RjVQQnlKYW53WkNTTTRmWTJFRkY0SWRTU3ZPRHNfamw1WE5kOGdwb0JpN0pYWDlHazlJVnptQUUyVjFNM0pXT3JCemxhX0JlQTBOTEhDaXNpVy1xbjNHY24wQ2RrRFhKZjVmQ0tPLW9HMzIxNzBXQkxZMEhxSWI1SlRCQ0hsQ2k0ZzhmLUlyMU5QMGhDNFEyN0toVzhiTW9qY3hIcWtqVU15MWVBZmJtNWRNOTF0QUdlbjdkZUd2NW5HX25QRUxTcVZLTjY3UFpTWUln?oc=5","date":"2023-06-23","type":"pipeline","source":"prnewswire.com","summary":"Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - prnewswire.com","headline":"Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQN2ozMWlmUjZVa3MySFBlbWExSTNpSGdKeVlQaXlva0YxZVhIU3lTR1VTWGRCXzBNbDZxekdpY19JODVOV0h6X1BsZ2FjSHB6SDVqeFhuMTFva3lEeFNFR3gyaF91OWRCLUZmdU44MjEtc0VKOVljZXZSMEhDUy02dkY5djVfbUdFYjNmek9HMA?oc=5","date":"2022-06-22","type":"pipeline","source":"Labiotech.eu","summary":"ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug - Labiotech.eu","headline":"ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNN0hQTHRUa1ltYzN3RUt6WGU0UTNpS014ZVlEUVFQSnFHcFRibjlTeXVHV0xTX3FUM1hJMkRZOXVRaDE3dURyRUhOYlEtWG9tUkRpVHUzTy03TDFob3NSSG44Q0xiSjNwWlV5Ym5pZ0tpc0hOTjlTN0VTYXRQTktmSWk2cFFKd2xF?oc=5","date":"2018-12-02","type":"pipeline","source":"C&EN","summary":"C&EN’s Year in Pharma 2018 - C&EN","headline":"C&EN’s Year in Pharma 2018 - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQXA2RGxRSm9hNnJSNVNsVTgwa3dFUGI5OWVhSFoxeWp3anRuS3dmM2pDb3FaSzREMW9EQWJtbHZUNXFrQ3JTSFhmcDBsd3F4RWV0dEd4X2YtbWpydUlkSzNoa3JRbVNwWk1zeXJyOEpGQUdRaW1CSkxvNVV2VjV1NElzT3NSVGluWXFmRVFpajk1RTV6?oc=5","date":"2018-03-16","type":"trial","source":"fiercebiotech.com","summary":"Lundbeck to buy Prexton for phase 2 Parkinson’s drug - fiercebiotech.com","headline":"Lundbeck to buy Prexton for phase 2 Parkinson’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOeU5zeGJWSTVSdV9iWlM2b0JMczJEWkQ2SFpMaE5GZWhFN0pwcjB5VjAtSWhNSGh5cXhsUGthWEs5QmlnM0tVdXE2UTE4NTN5YUk0ODhkcUxWV2tLUWdmY2R5UzhwWkstNEdZNWFSSmh1ODRfYlJDblNNNWl5aWx5NS00WWJDYzhBaHVDd2dxWDhaMWpfMFVYdW5ZdWZPM3Y5M2hQSg?oc=5","date":"2018-03-16","type":"trial","source":"Clinical Trials Arena","summary":"Lundbeck buys Prexton Therapeutics alongside Parkinson’s drug - Clinical Trials Arena","headline":"Lundbeck buys Prexton Therapeutics alongside Parkinson’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxNX09qQXB1VmE4NHlnd3h0a0hCc2JocGJpV2pSaXViNnJjUmZ2eW5ZSmpOWkozdlNzOGFCc2lnVEF5aURBSmVPcHJoZkNNVy1RaWd2a2hZTHlLRGMwTS11STlIMnlFeGp3Ql84VXNZYWN2WHNPd2lnRGtQZ0FXZjhEN0k2RFhhT3RoUkZtNjRDVFkxRFlxZmVPNm15NEptSDA2OV83RS1kOWNmUHF6NlZnQVVJWHFtQ09wWGhLdG90bFBEV19oeTJEanJGRi1UWEwweFEzNWoxS0dVUUJ4dFNlWGliUmVzNnoxLWFkdEdqa09VRVNWMFJtSTJsV3Q3cnlad2lXdExxNG5UcU5zMUhmNm9rMU1TeEVOWmhkVU9jVkM3Ri1MZWRmTTBsRENNSjZrNFNRanJUa0xFZzN6dWRENnpLN096UVZ2aTNYZm15Ml8zaXI0SEMxV25XWU4?oc=5","date":"2018-03-16","type":"deal","source":"GlobeNewswire","summary":"Lundbeck to acquire Prexton Therapeutics adding foliglurax - GlobeNewswire","headline":"Lundbeck to acquire Prexton Therapeutics adding foliglurax","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5qeHlORkNoRXZLSHpUWURPNkVNNmRrbHFodF9QYUpEbHlMc0Vpb0RCdXdxM3ExQVdPYkNHNjhUWGM3V1BYVklkRXNwZ3NjNldSdE8ySUduX24ycEQ4NTJiM3ppS1E5WGpFTWZjWG1IQWI?oc=5","date":"2018-03-16","type":"deal","source":"BioSpace","summary":"Lundbeck Acquires Prexton Therapeutics - BioSpace","headline":"Lundbeck Acquires Prexton Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQd291RGZhMDdjOTdENVlSNlQwSFVaU1RBTS1fV0swYThiNFBIMWlzbktFUkNjS3R5a0VPS09zR2VYeERJWXB2M1l0MGlCZkJlYU5DV1JqTEVzZVJtSEVKVkxfU0dWZGdpYlRVelkxV0JUNFJqbzdSNWY3S05yTE5kWEF3MUlDQTJoS3VLeVVkaGR2bER1VEhJ?oc=5","date":"2018-03-16","type":"deal","source":"BioPharma Dive","summary":"Lundbeck bulks up neuro pipeline with Prexton buy - BioPharma Dive","headline":"Lundbeck bulks up neuro pipeline with Prexton buy","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}